Zhang Gao-Hong, Han Jian-Bao, Zhu Lin, Luo Rong-Hua, Zhang Xi-He, Chen Xin, Hu Ying-Jie, Fu Lin-Chun, Zheng Yong-Tang
Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650223 Yunnan China.
Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650223 Yunnan China ; Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, 650204 Yunnan China.
Chin Med. 2016 Jul 1;11:31. doi: 10.1186/s13020-016-0105-x. eCollection 2016.
Aikeqing (AKQ) has been shown in clinical studies to improve quality of life of HIV/AIDS patients, but anti-HIV activity has not been determined. The SHIV-infected macaque is an important animal model for testing antiviral drugs. This study aimed to determine the anti-HIV activity of AKQ in chronically SHIV89.6-infected Chinese rhesus macaques.
Nine Chinese rhesus macaques were inoculated intravenously with SHIV89.6 virus. At 11 weeks post-infection, the animals were arbitrarily divided into three groups: high-dose (AKQ 1.65 g/kg; n = 3), low-dose (AKQ 0.55 g/kg; n = 3), and control (water 1 mL/kg; n = 3). Treatment was administered by the intragastric gavage route once-daily for 8 weeks. Blood (5 mL) was collected biweekly. Viral loads were analyzed by real-time quantitative RT-PCR assays, and T cell counts were monitored by FACS analyses throughout the treatment.
AKQ induced a persistent decline (P = 0.02) in plasma viral loads during treatment in the high-dose group compared with their baseline levels, and cessation of the therapy caused viral load rebound to the pretreatment levels. No significant difference (P = 0.06) was found in the plasma viral loads during treatment in the low-dose group. The CD4(+) T cell counts and CD4/CD8 ratios remained at stable high levels during the treatment period.
AKQ reduced plasma viral loads in the SHIV89.6-infected Chinese rhesus macaque model.
临床研究表明，艾可清（AKQ）可改善HIV/AIDS患者的生活质量，但尚未确定其抗HIV活性。感染SHIV的猕猴是测试抗病毒药物的重要动物模型。本研究旨在确定AKQ对慢性感染SHIV89.6的中国恒河猴的抗HIV活性。
9只中国恒河猴经静脉接种SHIV89.6病毒。感染后11周，将动物随机分为三组：高剂量组（AKQ 1.65 g/kg；n = 3）、低剂量组（AKQ 0.55 g/kg；n = 3）和对照组（水1 mL/kg；n = 3）。通过灌胃途径每日给药一次，持续8周。每两周采集一次血液（5 mL）。通过实时定量RT-PCR分析病毒载量，并在整个治疗过程中通过FACS分析监测T细胞计数。
与基线水平相比，高剂量组在治疗期间AKQ诱导血浆病毒载量持续下降（P = 0.02），治疗停止后病毒载量反弹至治疗前水平。低剂量组在治疗期间血浆病毒载量无显著差异（P = 0.06）。治疗期间CD4(+) T细胞计数和CD4/CD8比值保持在稳定的高水平。
在感染SHIV89.6的中国恒河猴模型中，AKQ降低了血浆病毒载量。
